12 September 2023 Clinigen launches NaviGATE: an educational programme for rare diseasepatients and organisations Accessing hard to reach medicines for people who need them most...
10 August 2023 Clinigen divests global rights to four cancer support therapies to CNX Therapeutics Clinigen Limited (˜Clinigen™), the global pharmaceutical services company, has completed the...
Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million
Clinigen Limited (‘Clinigen’ or the ‘Company’), the global pharmaceutical services company, has agreed to acquire Drug Safety Navigator Inc. (‘DSN’), a specialist pharmacovigilance service provider based in the US. This acquisition enables Clinigen to add vital pharmacovigilance capabilities to its leading pharma services offering for pharmaceutical and biotech clients.
Clinigen Healthcare is recalling three batches of Mexiletine hydrochloride hard capsules, indicated for the treatment of documented arrhythmias, due to a potential risk of under- or overdose, which could have consequences for the safety of patients. The Class 1 Medicines Recall Notification was published by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
24 May 2022 Clinigen expands US site capacity in response to growing demand for Clinical Supplies Management services Clinigen Limited (‘Clinigen’ or the ‘Company’), the global pharmaceutical...
Clinigen and Deciphera ink distribution deal for GIST drug
BURLINGAME, Calif. & DUBLIN & LONDON--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today that lenzilumab is now available for certain hospitalized COVID-19 patients through its newly-launched Managed Access Program (“LenzMAP™”). Clinigen Group plc (“Clinigen”), a global pharmaceutical Services and Products company, is implementing the program. Lenzilumab is an investigational product and is not currently authorized or approved in any country.
(Reuters) - Britain’s Clinigen Group Plc has agreed to a sweetened takeover offer by UK-based private equity firm Triton, valuing the pharmaceutical services firm at about 1.3 billion pounds ($1.78 billion).
The cancer drug specialist Clinigen has agreed to a £1.2bn takeover deal from a London-based investment firm, becoming the latest big British company to be taken private.